127 related articles for article (PubMed ID: 37879249)
1. Identification of small compounds that inhibit multiple myeloma proliferation by targeting c-Maf transcriptional activity.
Asano K; Kikuchi K; Takehara M; Ogasawara M; Yoshioka Y; Ohnishi K; Iwata A; Shimizu S; Tanaka M
Biochem Biophys Res Commun; 2023 Dec; 684():149135. PubMed ID: 37879249
[TBL] [Abstract][Full Text] [Related]
2. Targeting the oncogenic transcription factor c-Maf for the treatment of multiple myeloma.
Jiang Q; Mao H; He G; Mao X
Cancer Lett; 2022 Sep; 543():215791. PubMed ID: 35700821
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the Otub1/c-Maf axis by the herbal acevaltrate induces myeloma cell apoptosis.
Sun T; Xu Y; Xu Z; Cao B; Zhang Z; Wang Q; Kong Y; Mao X
Cell Commun Signal; 2021 Feb; 19(1):24. PubMed ID: 33627137
[TBL] [Abstract][Full Text] [Related]
4. A novel transgenic mouse model of the human multiple myeloma chromosomal translocation t(14;16)(q32;q23).
Morito N; Yoh K; Maeda A; Nakano T; Fujita A; Kusakabe M; Hamada M; Kudo T; Yamagata K; Takahashi S
Cancer Res; 2011 Jan; 71(2):339-48. PubMed ID: 21224354
[TBL] [Abstract][Full Text] [Related]
5. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma.
Chesi M; Bergsagel PL; Shonukan OO; Martelli ML; Brents LA; Chen T; Schröck E; Ried T; Kuehl WM
Blood; 1998 Jun; 91(12):4457-63. PubMed ID: 9616139
[TBL] [Abstract][Full Text] [Related]
6. The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival.
He Y; Wang S; Tong J; Jiang S; Yang Y; Zhang Z; Xu Y; Zeng Y; Cao B; Moran MF; Mao X
J Biol Chem; 2020 Feb; 295(7):2084-2096. PubMed ID: 31822558
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Otub1/c-Maf axis for the treatment of multiple myeloma.
Xu Y; Xu M; Tong J; Tang X; Chen J; Chen X; Zhang Z; Cao B; Stewart AK; Moran MF; Wu D; Mao X
Blood; 2021 Mar; 137(11):1478-1490. PubMed ID: 32842143
[TBL] [Abstract][Full Text] [Related]
8. C-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevance.
Rasmussen T; Knudsen LM; Dahl IM; Johnsen HE
Leuk Lymphoma; 2003 Oct; 44(10):1761-6. PubMed ID: 14692531
[TBL] [Abstract][Full Text] [Related]
9. Mebendazole elicits potent antimyeloma activity by inhibiting the USP5/c-Maf axis.
Chen XH; Xu YJ; Wang XG; Lin P; Cao BY; Zeng YY; Wang Q; Zhang ZB; Mao XL; Zhang T
Acta Pharmacol Sin; 2019 Dec; 40(12):1568-1577. PubMed ID: 31197245
[TBL] [Abstract][Full Text] [Related]
10. Identification of primary MAFB target genes in multiple myeloma.
van Stralen E; van de Wetering M; Agnelli L; Neri A; Clevers HC; Bast BJ
Exp Hematol; 2009 Jan; 37(1):78-86. PubMed ID: 19013005
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.
Hurt EM; Wiestner A; Rosenwald A; Shaffer AL; Campo E; Grogan T; Bergsagel PL; Kuehl WM; Staudt LM
Cancer Cell; 2004 Feb; 5(2):191-9. PubMed ID: 14998494
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the deubiquitinase USP5 leads to c-Maf protein degradation and myeloma cell apoptosis.
Wang S; Juan J; Zhang Z; Du Y; Xu Y; Tong J; Cao B; Moran MF; Zeng Y; Mao X
Cell Death Dis; 2017 Sep; 8(9):e3058. PubMed ID: 28933784
[TBL] [Abstract][Full Text] [Related]
13. Anti-bacterial and anti-viral nanchangmycin displays anti-myeloma activity by targeting Otub1 and c-Maf.
Xu Y; Sun T; Zeng K; Xu M; Chen J; Xu X; Zhang Z; Cao B; Tang X; Wu D; Kong Y; Zeng Y; Mao X
Cell Death Dis; 2020 Sep; 11(9):818. PubMed ID: 32999280
[TBL] [Abstract][Full Text] [Related]
14. MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.
Qiang YW; Ye S; Chen Y; Buros AF; Edmonson R; van Rhee F; Barlogie B; Epstein J; Morgan GJ; Davies FE
Blood; 2016 Dec; 128(25):2919-2930. PubMed ID: 27793878
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitination of the transcription factor c-MAF is mediated by multiple lysine residues.
Chen G; Xu X; Tong J; Han K; Zhang Z; Tang J; Li S; Yang C; Li J; Cao B; Zhou H; Wu D; Moran MF; Mao X
Int J Biochem Cell Biol; 2014 Dec; 57():157-66. PubMed ID: 25448412
[TBL] [Abstract][Full Text] [Related]
16. The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis.
Xu Y; Zhang Z; Li J; Tong J; Cao B; Taylor P; Tang X; Wu D; Moran MF; Zeng Y; Mao X
J Hematol Oncol; 2017 Jul; 10(1):132. PubMed ID: 28673317
[TBL] [Abstract][Full Text] [Related]
17. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.
Tai YT; Soydan E; Song W; Fulciniti M; Kim K; Hong F; Li XF; Burger P; Rumizen MJ; Nahar S; Podar K; Hideshima T; Munshi NC; Tonon G; Carrasco RD; Afar DE; Anderson KC
Blood; 2009 Apr; 113(18):4309-18. PubMed ID: 19196658
[TBL] [Abstract][Full Text] [Related]
18. Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma.
Martin LD; Harizanova J; Righolt CH; Zhu G; Mai S; Belch AR; Pilarski LM
Genes Chromosomes Cancer; 2013 Jun; 52(6):523-37. PubMed ID: 23460268
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNA ANGPTL1-3 promotes multiple myeloma bortezomib resistance by sponging miR-30a-3p to activate c-Maf expression.
Nian F; Zhu J; Chang H
Biochem Biophys Res Commun; 2019 Jul; 514(4):1140-1146. PubMed ID: 31103265
[TBL] [Abstract][Full Text] [Related]
20. 16q23/MAF Gene Deletion Is a Frequent Cytogenetic Abnormality in Multiple Myeloma Associated With IgH Deletion but Significantly Lower Incidence of High-Risk Translocations.
Rana S; Sreedharanunni S; Panakkal V; Singh Sachdeva MU; Varma N; Malhotra P
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e398-e401. PubMed ID: 33309247
[No Abstract] [Full Text] [Related]
[Next] [New Search]
